EGFR and breast cancer: Since it is likely that the specific molecular landscape of BC cell subtypes (relative expression levels and activation status of ErbB family members, CXCR4/ACKR3 expression patterns and internalization extent, oncogenic mutations, interactors, spacio-temporal activation determinants, availability of downstream effectors) would be key in this regard [11,33], it would be important to further investigate these issues in endogenous cell model systems, to help design future therapeutic strategies targeting these receptor families.